DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valued, ...

Fintel reports that on December 11, 2025, Citigroup maintained coverage of DexCom (NasdaqGS:DXCM) with a Buy recommendation.

BofA raised the firm’s price target on DexCom (DXCM) to $90 from $80 and keeps a Buy rating on the shares post the Q3 report. DexCom did a good job instilling confidence in its 2025 revenue target ...

In a report released yesterday, Lee Hambright from Bernstein maintained a Buy rating on Dexcom, with a price target of $84.00. The company’s shares closed yesterday at $66.96.

DexCom's growth rate has been accelerating for multiple quarters, and recently came in at around 22%. A rise in GLP-1 drugs has some investors concerned that DexCom's growth opportunities may be ...

Piper Sandler analyst Matt O’Brien raised the firm’s price target on DexCom (DXCM) to $100 from $90 and keeps an Overweight rating on the shares. The firm notes the company reported full Q4 results, ...

Investing.com - TD Cowen has reiterated its Buy rating on DexCom (NASDAQ:DXCM) with a price target of $100.00 ahead of the company’s third-quarter earnings report, scheduled for October 30. According ...

Morgan Stanley upgrades shares of the medtech to Overweight from Equal Weight.

DexCom's Q1 2025 earnings show strong growth potential, but cost pressures are impacting margins, leading me to lower my rating from buy to hold. Despite demographic tailwinds and a growing market, ...

The medical device maker has already made impressive gains. A planned stock split may make shares even more attractive to investors. DexCom's robust business performance is reflected in its surging ...